TMBC

Taiwan Bio-Manufacturing Corp (TBMC), headquartered in Taipei, specializes in biomanufacturing services focusing on complex modalities like nucleic acid gene therapy and cell therapy, serving biotechnology and pharmaceutical companies globally. Taiwan Bio-Manufacturing Corp (TBMC) is engaged in biomanufacturing, providing services designed to support the pharmaceutical industry's production of biologics. Founded in 2023 in Taipei, Taiwan, TBMC has executed one deal, raising TWD 1 billion in venture funding in August 2023 from the National Development Fund of the Executive Yuan, which constitutes the total amount raised by the company. The company is led by a management team with expertise in biomanufacturing, although specific founder details are not disclosed.

Taiwan Bio-Manufacturing Corporation (TBMC) specializes in end-to-end biomanufacturing services with a focus on complex modalities, including nucleic acid gene therapy, cell therapy, and protein drugs. Their core offerings integrate technologies to provide comprehensive solutions for the biopharmaceutical industry, addressing challenges in producing biologics with high-quality and efficient manufacturing processes. TBMC serves a diverse client base that includes biotechnology firms and large pharmaceutical companies, operating in North America, Europe, and Asia-Pacific. TBMC generates revenue primarily through business-to-business (B2B) transactions, providing biomanufacturing services on a contract basis.

Clients engage TBMC through partnerships or contractual agreements outlining the services, timelines, and costs. The company’s revenue model includes service fees for gene therapy, cell therapy, and protein drug production, with pricing based on manufacturing complexity and client project requirements, facilitating long-term collaborations. With the recent funding round completed in August 2023, where TMBC raised TWD 1 billion, the company plans to enhance its biomanufacturing capabilities and develop new products. Specific details on upcoming products and anticipated release dates have not been disclosed.

Additionally, TMBC aims to expand into new markets in North America and Europe by the end of 2024, leveraging the fresh capital from the funding to support these initiatives.